AceLink Therapeutics Announces AL01211 Granted Breakthrough Therapy Status in China for Fabry Disease
AceLink Therapeutics, a clinical-stage drug development company, announced today that AL01211, the company's innovative oral, small molecule drug that is being developed for Fabry disease, was granted “Breakthrough Therapy designation” by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA).
AceLink Therapeutics Announces Publication of Phase 1 Clinical Trial Data Evaluating AL01211 in Healthy Volunteers
AceLink Therapeutics, Inc., a clinical-stage biopharmaceutical company developing next generation oral substrate reduction therapies (SRTs), today announced that the findings from their Phase 1 study of AL01211 in healthy volunteers have been published in the peer-reviewed journal Clinical Pharmacology in Drug Development, a journal of the American College of Clinical Pharmacy.
